 |
| Main Menu | News By Date | News By Supplier | News By Category | About Us |
|
KETOCYTONYX REPORTS POSITIVE PHASE I STUDY OF NEUROPROTECTANT
Ketocytonyx, Inc., a pharmaceutical development company focused on cell protection therapeutics, today announced the successful completion of a Phase I clinical study of KTX 0101, its lead therapeutic targeting prevention of cognitive impairment in patients undergoing coronary artery bypass graft surgery. Twenty healthy volunteers were enrolled into this dose-escalation study. KTX 0101 was found to be well tolerated by all volunteers with no serious adverse events reported. Drug pharmacokinetics were as predicted. In addition, statistically significant changes, compared to placebo, seen in the electroencephalogram recording indicated that KTX 0101 had a pharmacodynamic effect on the central nervous system. This effect is similar to that seen in patients when hypothermia was used to provide neuroprotection for patients undergoing CABG surgery and following head injury. Hypothermia has been reported to improve functional outcome following traumatic brain injury. Dr Keith Martin, President of KetoCytonyx, commented: “We are very pleased with the results of our first clinical study, which show that KTX 0101 was very well tolerated at all dose levels. The effect on the EEG recorded from the central nervous system also provides the first data in man to suggest a potential neuroprotectant effect. We are now planning the further clinical development of KTX 0101 to confirm safety and proof of principle as a neuroprotectant in Phase I b and Phase II studies.” Prof Stanton Newman, Member of the KetoCytonyx Scientific Advisory Board, added: “The demonstration that the infusion of KTX 0101 has a significant effect on the EEG suggests that KetoCytonyx approach to neuroprotection for patients undergoing coronary artery bypass surgery holds great promise”.
|
| ©2008 New Materials International |